



Third Quarter 2025 Earnings



October 27, 2025



Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded [hyperlink](#) and is available on the "Financial Information" section of our website at www.revvity.com.

Key Takeaways

Innovation

New screening program for
Type 1 Diabetes

New **AI driven offerings** for
in vivo & base editing

Market

Stable **Pharma & Academic**
market **demand**

Strong **Diagnostic** trends
outside of China


Performance

Software & Newborn driving
solid overall growth

EPS above expectations with
strong **Cash Flow** generation


*A Scientific Solutions Company Helping to Solve The World's Greatest Health Challenges
From Discovery to Development, and Diagnosis to Cure*

3Q25 Revenue Highlights





Segments

● Diagnostics ● Life Sciences




Geographic

● AMERICAS ● APAC ● EU



Product Mix

● Recurring ● Non-recurring




3Q25 Financial Results

REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
\$699M	26.1%	\$1.18	\$120M
↑ +2% y/y	↓ -220bps y/y	↓ -8% y/y	\$354M YTD
Organic: +1% M&A: 0% FX: +1%	Adj. Gross Margin: 58.7% -300bps y/y	Adj. Tax Rate: 15.0%	YTD FCF % Adj. NI: 89%
		Adj. Net Interest & Other: \$22M	

Life Sciences


● LIFE SCIENCE SOLUTIONS ● SOFTWARE



REVENUE	ADJUSTED OP MARGINS
0% Organic Growth	29.5%
Reported: 1% M&A: 0% FX: +1%	-310bps y/y

- +LSD growth from Pharma/Biotech, -LSD decline from Academic/Gov't
- -LSD decline in Life Science Solutions consistent with YTD trends
- +DD software growth driven by new orders, strong renewals and SaaS performance
- Margin pressure yr/yr driven by lower volumes, FX and strategic investments

Diagnostics





REVENUE	ADJUSTED OP MARGINS
2% Organic Growth	25.1%
Reported: 3% M&A: 0% FX: +2%	-210 bps y/y

- -LSD ImmunoDX globally; +HSD growth ex China, -DD in China
- +MSD Reproductive Health driven by strength in newborn
- Margin pressure yr/yr driven by tariffs, product mix, and FX

2025 Financial Guidance

REVENUE	\$2.83B - \$2.88B
	Reported: 3% to 5%
	Organic: 2% to 4%
	FX: 1%, M&A: 0%
ADJUSTED OP. MARGIN	27.1-27.3%
ADJUSTED EPS	\$4.90 - \$5.00
	Adj. Net interest expense, other: ~\$83M
	Adjusted tax rate: ~17%
	Average diluted share count: ~117M





Revvity.com